Effectiveness of a Saffron and Withania Supplement on Mood in Women With Mild-to-Moderate Anxiety During the COVID-19 Lockdown

IF 4.7 2区 医学 Q1 PSYCHIATRY Depression and Anxiety Pub Date : 2024-11-10 DOI:10.1155/2024/3661412
Cristina Pages-García, M. Cristina De Almagro, Jorge Ruiz-Moreno, Roser De Castellar
{"title":"Effectiveness of a Saffron and Withania Supplement on Mood in Women With Mild-to-Moderate Anxiety During the COVID-19 Lockdown","authors":"Cristina Pages-García,&nbsp;M. Cristina De Almagro,&nbsp;Jorge Ruiz-Moreno,&nbsp;Roser De Castellar","doi":"10.1155/2024/3661412","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background:</b> A nutritional supplement based on medicinal plants (saffron and ashwagandha), tryptophan, and vitamin B6 could contribute to alleviating/improving mood and associated disorders. The aim of this study was to evaluate the potential benefits of this combination supplement. During the study period, participants underwent a period of forced home confinement due to the COVID-19 pandemic, which represented an unexpected impact factor.</p>\n <p><b>Methods:</b> This open-label prospective trial enrolled a cohort of female employees who reported mild to moderate anxiety. The primary objective was to evaluate changes in the level of anxiety using the adapted Hamilton Anxiety Rating Scale (HARS) after 12 weeks of regular supplementation with Safromotive (two tablets daily, for 12 weeks). The secondary objectives were to evaluate health-related quality of life (HRQoL) and tolerability.</p>\n <p><b>Results:</b> In total, 46 women with a mean age of 45.0 (6.5) years were included. A statistically significant improvement in HARS was observed, with a 7.5-unit decrease from baseline to 12 weeks (<i>p</i>  &lt; 0.0001) and from 4 to 12 weeks of supplement intake (<i>p</i> = 0.0058). However, no significant changes were found during the lockdown period (between weeks 8 and 12 of the study). No relationship was found between women’s sociodemographic characteristics and the HARS total score. A significant reduction in the HRQoL questionnaire score of 1.2 units was observed between baselines and 12 weeks of treatment (<i>p</i> = 0.0273). At the end of the study, 78.6% of the women reported consistency the supplement intake during the study course.</p>\n <p><b>Conclusion:</b> This nutritional supplement composed of saffron, ashwagandha, tryptophan, and vitamin B6 appears to improve anxiety and HRQoL, but confinement could have impacted the evolution of the outcome.</p>\n </div>","PeriodicalId":55179,"journal":{"name":"Depression and Anxiety","volume":"2024 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3661412","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Depression and Anxiety","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/3661412","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A nutritional supplement based on medicinal plants (saffron and ashwagandha), tryptophan, and vitamin B6 could contribute to alleviating/improving mood and associated disorders. The aim of this study was to evaluate the potential benefits of this combination supplement. During the study period, participants underwent a period of forced home confinement due to the COVID-19 pandemic, which represented an unexpected impact factor.

Methods: This open-label prospective trial enrolled a cohort of female employees who reported mild to moderate anxiety. The primary objective was to evaluate changes in the level of anxiety using the adapted Hamilton Anxiety Rating Scale (HARS) after 12 weeks of regular supplementation with Safromotive (two tablets daily, for 12 weeks). The secondary objectives were to evaluate health-related quality of life (HRQoL) and tolerability.

Results: In total, 46 women with a mean age of 45.0 (6.5) years were included. A statistically significant improvement in HARS was observed, with a 7.5-unit decrease from baseline to 12 weeks (p  < 0.0001) and from 4 to 12 weeks of supplement intake (p = 0.0058). However, no significant changes were found during the lockdown period (between weeks 8 and 12 of the study). No relationship was found between women’s sociodemographic characteristics and the HARS total score. A significant reduction in the HRQoL questionnaire score of 1.2 units was observed between baselines and 12 weeks of treatment (p = 0.0273). At the end of the study, 78.6% of the women reported consistency the supplement intake during the study course.

Conclusion: This nutritional supplement composed of saffron, ashwagandha, tryptophan, and vitamin B6 appears to improve anxiety and HRQoL, but confinement could have impacted the evolution of the outcome.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
藏红花和睡莲属植物补充剂对 COVID-19 禁闭期间轻度至中度焦虑女性情绪的影响
背景:一种基于药用植物(藏红花和灰树花)、色氨酸和维生素 B6 的营养补充剂有助于缓解/改善情绪和相关疾病。本研究旨在评估这种复合补充剂的潜在益处。在研究期间,参与者因 COVID-19 大流行而被迫在家休养,这是一个意想不到的影响因素。 研究方法这项开放标签前瞻性试验招募了一批报告有轻度至中度焦虑的女性员工。首要目标是在定期补充 Safromotive(每天两片,共 12 周)12 周后,使用改编的汉密尔顿焦虑评定量表(HARS)评估焦虑程度的变化。次要目标是评估与健康相关的生活质量(HRQoL)和耐受性。 研究结果共纳入 46 名妇女,平均年龄为 45.0 (6.5) 岁。从统计学角度看,HARS 有明显改善,从基线到 12 周减少了 7.5 个单位(p < 0.0001),从摄入补充剂 4 周到 12 周减少了 7.5 个单位(p = 0.0058)。然而,在禁食期(研究的第 8 周至第 12 周之间)没有发现明显的变化。妇女的社会人口特征与 HARS 总分之间没有关系。从基线到治疗 12 周期间,HRQoL 问卷得分明显降低了 1.2 个单位(p = 0.0273)。研究结束时,78.6% 的妇女表示在研究过程中坚持摄入补充剂。 结论这种由藏红花、芦荟、色氨酸和维生素 B6 组成的营养补充剂似乎可以改善焦虑和 HRQoL,但禁闭可能会影响结果的变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Depression and Anxiety
Depression and Anxiety 医学-精神病学
CiteScore
15.00
自引率
1.40%
发文量
81
审稿时长
4-8 weeks
期刊介绍: Depression and Anxiety is a scientific journal that focuses on the study of mood and anxiety disorders, as well as related phenomena in humans. The journal is dedicated to publishing high-quality research and review articles that contribute to the understanding and treatment of these conditions. The journal places a particular emphasis on articles that contribute to the clinical evaluation and care of individuals affected by mood and anxiety disorders. It prioritizes the publication of treatment-related research and review papers, as well as those that present novel findings that can directly impact clinical practice. The journal's goal is to advance the field by disseminating knowledge that can lead to better diagnosis, treatment, and management of these disorders, ultimately improving the quality of life for those who suffer from them.
期刊最新文献
A Longitudinal Correlational Study of Psychological Resilience, Depression Disorder, and Brain Functional–Structural Hybrid Connectome in Breast Cancer Associations of Changes in Alcohol Consumption on the Risk of Depression/Suicide Among Initial Nondrinkers Effectiveness of a Saffron and Withania Supplement on Mood in Women With Mild-to-Moderate Anxiety During the COVID-19 Lockdown Correlation Between Anxiety and Serum Thyroid Hormone Levels in Patients With Papillary Thyroid Carcinoma Undergoing Microwave Ablation The Bridge Symptoms of Work–Family Conflict, Sleep Disorder, and Job Burnout: A Network Analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1